Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Descamps

Showing results (101-110 of 126) with videos related to

Pageof 13
Sort By:
Journal of Clinical Microbiology|February 5, 2010
Evaluation of an upgraded version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test for HIV-1 load quantificationF Damond, V Avettand-Fenoel, G Collin, et al.
AIDS Research and Human Retroviruses|January 12, 2001
HIV RNA and HIV DNA in peripheral blood mononuclear cells are consistent markers for estimating viral load in patients undergoing long-term potent treatmentM Burgard, J Izopet, B Dumon, et al.
HIV Clinical Trials|February 3, 2006
Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS studyR Landman, D Descamps, G Peytavin, et al.
Annals of Internal Medicine|October 3, 1998
Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infectionC Katlama, M A Valantin, S Matheron, et al.
Pathologie-Biologie|August 19, 2000
[Conditions of "thymidine analog mutations" (TAMs) in naive patients treated with different combinations of d4T]M Mouroux, J Izopet, D Descamps, et al.
Antimicrobial Agents and Chemotherapy|May 17, 2001
Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitorsB Masquelier, E Race, C Tamalet, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 12, 2020
Challenges and issues about organizing a hospital to respond to the COVID-19 outbreak: experience from a French reference centreN Peiffer-Smadja, J-C Lucet, G Bendjelloul, et al.
The Journal of Antimicrobial Chemotherapy|January 31, 2013
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 virusesS Lambert-Niclot, C Charpentier, A Storto, et al.
Antiviral Therapy|January 26, 2002
Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapyM Mouroux, D Descamps, J Izopet, et al.
The Journal of Antimicrobial Chemotherapy|April 9, 2008
Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavirB Masquelier, K L Assoumou, D Descamps, et al.
Pageof 13

Showing results (101-110 of 126) with videos related to

Sort By:
Pageof 13
Journal of Clinical Microbiology|February 5, 2010
Evaluation of an upgraded version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test for HIV-1 load quantificationF Damond, V Avettand-Fenoel, G Collin, et al.
AIDS Research and Human Retroviruses|January 12, 2001
HIV RNA and HIV DNA in peripheral blood mononuclear cells are consistent markers for estimating viral load in patients undergoing long-term potent treatmentM Burgard, J Izopet, B Dumon, et al.
HIV Clinical Trials|February 3, 2006
Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS studyR Landman, D Descamps, G Peytavin, et al.
Annals of Internal Medicine|October 3, 1998
Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infectionC Katlama, M A Valantin, S Matheron, et al.
Pathologie-Biologie|August 19, 2000
[Conditions of "thymidine analog mutations" (TAMs) in naive patients treated with different combinations of d4T]M Mouroux, J Izopet, D Descamps, et al.
Antimicrobial Agents and Chemotherapy|May 17, 2001
Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitorsB Masquelier, E Race, C Tamalet, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 12, 2020
Challenges and issues about organizing a hospital to respond to the COVID-19 outbreak: experience from a French reference centreN Peiffer-Smadja, J-C Lucet, G Bendjelloul, et al.
The Journal of Antimicrobial Chemotherapy|January 31, 2013
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 virusesS Lambert-Niclot, C Charpentier, A Storto, et al.
Antiviral Therapy|January 26, 2002
Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapyM Mouroux, D Descamps, J Izopet, et al.
The Journal of Antimicrobial Chemotherapy|April 9, 2008
Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavirB Masquelier, K L Assoumou, D Descamps, et al.
Pageof 13